NRXBF NurExone Biologic Inc.

$0.43

NurExone Biologic Inc. (NRXBF) is expected to report earnings on November 30, 2026, before the market open. The consensus earnings estimate is a loss of $0.01 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +11.7% since its last earnings release on August 31, 2026.

NurExone Biologic Reported In-line with Estimates
Monday, August 31, 2026 · 12:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 30
Monday · Before Open
Earnings Whisper
-
vs ($0.01)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.44

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About NurExone Biologic Inc.

NurExone Biologic Inc. is a pharmaceutical company which involved in developing a platform for biologically guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company's principal product includes ExoPTEN. NurExone Biologic Inc. is based in HAIFA, Israel.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.